Last reviewed · How we verify

NCT06364683

Coronary Artery Disease and Exercise Adherence

Completed Last updated 22 July 2025
What this trial tests

trial testing Survey study in Adherence, Treatment in 208 participants. Completed in 13 May 2025.

Timeline
13 May 2024
Primary endpoint
13 November 2024
13 May 2025

Quick facts

Lead sponsorAbant Izzet Baysal University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment208
Start date13 May 2024
Primary completion13 November 2024
Estimated completion13 May 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Abant Izzet Baysal University

Who can join

Adults 18 to 74, any sex, with Adherence, Treatment or Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to determine the factors affecting exercise adherence in patients with coronary artery disease (CAD). For this purpose, the following measurement tools will be used respectively: (1) "Patient Information Form" including sociodemographic characteristics of the patients and medical information related to the disease, (2) the Exercise Adherence Rating Scale (EARS), (3) Exercise Self-Efficacy Scale (ESE) and, (4) Turkish-Health Literacy Survey Europe-Q12 (HLS-EU-19-12Q-TR). Statistical analyses will be carried out by descriptive statistics (number, percentage, mean, standard deviation, etc.), correlation analysis and regression analysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Survey study

Trials testing the same drug.

Other recruiting trials for Adherence, Treatment

Currently open trials in the same condition.

Other Abant Izzet Baysal University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06364683.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing